Edison Issues Outlook on AFT Pharmaceuticals (AFT)
LONDON, UK / ACCESSWIRE / November 26, 2019 / AFT Pharmaceuticals is a New Zealand-based specialty pharmaceutical company that currently sells over 130 prescription specialty generics and OTC products through its own salesforce in New Zealand, Australia and South-East Asia. The company recently reported its H120 results. Operating revenue grew by a strong 22.1% year-on-year as there was growth across all regional segments, notably South-East Asia and Rest of World, which grew by 111.9% and 64.4%, respectively. Importantly, the company reported an operating profit of NZ$13.7m (with all regions contributing profit), up from a loss of NZ$0.1m in the first half of FY19.
We are increasing our valuation from NZ$495m or NZ$5.09 per share to NZ$539m or NZ$5.53 per share, mainly due to rolling forward our NPV and increased revenue estimates, particularly in South-East Asia, as they were stronger compared to our expectations. This increase was offset in part by slightly higher net debt.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Maxim Jacobs, +1 646 653 7027
Learn more at www.edisongroup.com and connect with Edison on:
SOURCE: Edison Investment Research Limited
View source version on accesswire.com: